FDX
41
4
NWS
75
6
PNC
52
2
CLX
56
6
NDAQ
62
3
PGR
54
-5
SNA
39
-9
SEE
29
4
QRVO
29
3
ETR
65
5
ABBV
39
2
IPG
36
5
DTE
38
2
EXPD
34
5
MCHP
39
2
NTRS
45
15
KMI
61
4
CA
31
3
PHM
52
6
FRT
53
5
FDX
41
4
NWS
75
6
PNC
52
2
CLX
56
6
NDAQ
62
3
PGR
54
-5
SNA
39
-9
SEE
29
4
QRVO
29
3
ETR
65
5
ABBV
39
2
IPG
36
5
DTE
38
2
EXPD
34
5
MCHP
39
2
NTRS
45
15
KMI
61
4
CA
31
3
PHM
52
6
FRT
53
5
Financhill
Back

Vistagen Therapeutics 10K Form

Sell
14

VTGN
Vistagen Therapeutics

Last Price:
$2.09
Seasonality Move:
-15.14%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive VTGN News And Ratings

See the #1 stock for the next 7 days that we like better than VTGN

VTGN Financial Statistics

Sales & Book Value

Annual Sales: $1.1M
Cash Flow: $-10.3M
Price / Cash Flow: 0
Annual Sales: $2.86
Price / Book: 0.75

Profitability

EPS (TTM): -1.58230
Net Income (TTM): $-47.3M
Gross Margin: $0
Return on Equity: -45.8%
Return on Assets: -42.01%

Vistagen Therapeutics Earnings Forecast

Key Vistagen Therapeutics Financial Ratios

  • The Selling, General & Administrative Expenses for VTGN have been equal to 1,321.71% of Gross Profit Margin.
  • The Research & Development expenses have been 1,881.77% of Revenue.
  • Per Share Earnings over the last 16 years have been positive in 8 years.

Vistagen Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: VTGN
CUSIP: 92840H
Website: vistagen.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 9.35
Quick Ratio: 9.2

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

VTGN Technical Analysis vs Fundamental Analysis

Sell
14
Vistagen Therapeutics (VTGN) is a Sell

Is Vistagen Therapeutics a Buy or a Sell?